GLS Gelesis Holdings, Inc.

Gelesis, Inc., a biotechnology company, develops therapies to treat the genesis of gastrointestinal (GI) related chronic diseases. It develops a mechanobiology technology platform to treat obesity and other chronic diseases related to the GI pathway. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and chronic idiopathic constipation. Gelesis, Inc. was incorporated in 2006 and is based in Boston, Massachusetts.

$4.88  -0.07 (-1.41%)
As of 05/24/2022 11:49:24 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  08/24/2020
Outstanding shares:  72,390,413
Average volume:  86,509
Market cap:   $359,780,353
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -5.81
PB ratio:   35.61
PS ratio:   0.05
Return on equity:   5.02%
Net income %:   -0.22%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy